Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Equity: 2016-2025

Historic Return on Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to -0.61%.

  • Intellia Therapeutics' Return on Equity fell 10.00% to -0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.61%, marking a year-over-year decrease of 10.00%. This contributed to the annual value of -0.51% for FY2024, which is 10.00% down from last year.
  • Per Intellia Therapeutics' latest filing, its Return on Equity stood at -0.61% for Q3 2025, which was up 3.87% from -0.63% recorded in Q2 2025.
  • Intellia Therapeutics' Return on Equity's 5-year high stood at -0.25% during Q4 2021, with a 5-year trough of -0.63% in Q2 2025.
  • For the 3-year period, Intellia Therapeutics' Return on Equity averaged around -0.49%, with its median value being -0.47% (2024).
  • Per our database at Business Quant, Intellia Therapeutics' Return on Equity grew by 15bps in 2021 and then decreased by 21bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' Return on Equity (Quarterly) stood at -0.25% in 2021, then decreased by 19bps to -0.44% in 2022, then declined by 1bps to -0.45% in 2023, then decreased by 8bps to -0.53% in 2024, then fell by 10bps to -0.61% in 2025.
  • Its last three reported values are -0.61% in Q3 2025, -0.63% for Q2 2025, and -0.60% during Q1 2025.